ABVC BioPharma, Inc. (ABVC): Price and Financial Metrics
GET POWR RATINGS... FREE!
ABVC Stock Price Chart Interactive Chart >
ABVC Price/Volume Stats
| Current price | $1.95 | 52-week high | $11.69 |
| Prev. close | $2.01 | 52-week low | $1.95 |
| Day low | $1.95 | Volume | 68,200 |
| Day high | $2.02 | Avg. volume | 68,785 |
| 50-day MA | $2.41 | Dividend yield | N/A |
| 200-day MA | $2.78 | Market Cap | 59.10M |
ABVC BioPharma, Inc. (ABVC) Company Bio
American BriVision (Holding) Corporation, a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, a combination therapy for triple negative breast cancer; ABV-1504 for major depressive disorders; ABV-1505 for attention deficit hyperactivity disorder; ABV-1703 for the treatment of pancreatic cancer; ABV-1702 to treat myelodysplastic syndromes; ABV-1601 for treating depression in cancer patients; and ABV-1701 Vitargus for the treatment of retinal detachment or vitreous hemorrhage. It has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company was incorporated in 2015 and is based in Fremont, California. American BriVision (Holding) Corporation is a subsidiary of YuanGene Corporation.
Latest ABVC News From Around the Web
Below are the latest news stories about Abvc Biopharma Inc that investors may wish to consider to help them evaluate ABVC as an investment opportunity.
ABVC BioPharma Announces Principal Investigator Meeting for Phase II Part 2 ADHD Clinical StudyFremont, CA, Feb. 02, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced that the Principal Investigator Meeting for the ABV-1505 Phase II Part 2 ADHD clinical study will be held on February 14, 2022. Principal investigators from the University of California San Francisco (“UCSF”) Medical Center and five prestigious Taiwan medi |
ABVC BioPharma Selects Additional Vitargus® Phase II Study SitesThailand Sites Join Australian Sites Confirmed to Participate in the Study Fremont, CA, Jan. 05, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced two clinical sites in Thailand have been selected to participate in the Phase II clinical study of Vitargus®, the first bio-degradable vitreous substitute intended to facilitate ret |
ABVC BioPharma’s Vitreous Substitute Vitargus Presented at 14th APVRS CongressFremont, CA, Dec. 22, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced that Vitargus®, the world's first bio-degradable vitreous substitute, was presented by Dr. Andrew Chang, MD, Ph.D on December 11, 2021 at the 14th Asia-Pacific Vitreo-Retina Society (“APVRS”) Congress. APVRS, one of the most prestigious ophthalmology confe |
ABVC BioPharma Medical Device Vitargus Receives Taiwan National Innovation AwardFremont, CA, Dec. 15, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced that Vitargus®, its vitreous substitute intended to facilitate retina re-attachment surgery, received the 2021 National Innovation and Renewal of Diligence award from the Institute for Biotechnology and Medicine Industry (IBMI) of Taiwan. The award was presented at the Taiwan Medical Technology Exhibition on December 2, 2021 at the Taipei Nangang Exhibition Center. |
Why ABVC BioPharma Shares Are Trading Higher On Friday?ABVC BioPharma Inc (NASDAQ: ABVC) shares gained during the market trading session on continued momentum from yesterday's dietary supplement distribution deal and after a favorable report from Zacks Small-Cap Research. Yesterday, ABVC Biopharma announced that BioKey would produce dietary supplements derived from the maitake mushroom in tablet and liquid forms. In addition, BioKey has entered into a three-year distribution agreement with Define Biotech Co Ltd, Taiwan-based pharmaceutical marketing |
ABVC Price Returns
| 1-mo | -18.41% |
| 3-mo | -21.37% |
| 6-mo | -35.86% |
| 1-year | -64.55% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -42.48% |
| 2021 | -33.53% |
| 2020 | 16.70% |
| 2019 | -87.86% |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...